Auxilium Pharmaceuticals Announces Top-Line Results From Phase IV Trial Of Testim(R) In Patients With Type II Diabetes
MALVERN, Pa., June 15 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL - News), a specialty pharmaceutical company, today reported top-line results from its Phase IV randomized trial of Testim® 1%, its topical testosterone gel, treatment in patients with Type II diabetes.